Text Size

Advantages of efficacy and safety of fixed-dose tafluprost/timolol combination over fixed-dose latanoprost/timolol combination

Fuwa M., Ueda K., Akaishi T., Yamashita N., Kirihara T., Shimazaki A., Mano H., Kawazu K.


  • 2016
  • PLoS ONE
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Preclinical development

  • Affiliations

    Global Research and Development, Santen Pharmaceutical Co., Ltd., Ikoma-shi, Nara, Japan

Related Publications

24-Hour Evaluation of the Effectiveness and Tolerability of Preservative-Free Tafluprost-Timolol Fixed Combination in Open-Angle Glaucoma or Ocular Hypertensive Patients Previously Treated with Preserved Latanoprost

Oddone F, Tanga L, Giammaria S, Sabbatini L, Strianese A, Ferrazza M, Rossetti LM


MicroRNA profile of extracellular vesicles released by Müller glial cells

Lamb W D.B.; Eastlake K.; Luis J.; Sharif N.A. ; Khaw P. T.; Limb G. A.


Steroid-Induced Ocular Hypertension in Mice Is Differentially Reduced by Selective EP2, EP3, EP4, and IP Prostanoid Receptor Agonists

Sharif N.A.; Millar J.C.; Zode G.; Ota T.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022